Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11912-010-0128-x.pdf
Reference72 articles.
1. •• McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833. This article describes the pivotal experience with rituximab, the first antibody approved by the FDA for therapy of cancer.
2. Hagenbeek A, Gadeberg O, Johnson P, et al.: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008, 111:5486–5495.
3. Morschhauser F, Leonard JP, Fayad L, et al.: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J Clin Oncol 2009, 27:3346–3353.
4. Morschhauser F, Marlton P, Vitolo U, et al.: Interim results of a phase I/II study of ocrelizumab, a new humanized anti-CD20 antibody in patients with relapsed/refractory follicular non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts) 2007, 110:abstract 645.
5. Salles G, Morschhauser F, Cartron P, et al.: A phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Blood (ASH Annual Meeting Abstracts) 2008, 112:abstract 234.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma;Leukemia & Lymphoma;2013-05-15
2. Future Directions in Aggressive Lymphomas;Non-Hodgkin Lymphoma;2012-12-06
3. Antibody-Targeted Therapeutic Radionuclides in the Management of Colorectal Cancer;Nuclear Medicine Therapy;2012-07-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3